The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab
© 2010 Blackwell Publishing Ltd..
BACKGROUND: Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks.
AIM: We sought to investigate the efficacy of a once every 6 weeks' strategy compared with dose-doubling.
METHODS: This work was a multicentre retrospective study of infliximab-treated CD patients who required dose escalation. The clinical outcome of patients treated by intensification to 5 mg/kg/6 weeks (6-week group) was compared with the outcome of patients whose infliximab was double-dosed (10 mg/kg/8 weeks or 5 mg/kg/4 weeks).
RESULTS: Ninety-four patients (mean age: 29.8 years) were included in the study, 55 (59%) in the 6-week group and 39 (41%) in the double-dose group. Demographics and disease characteristics were similar between the two groups, although patients with re-emerging symptoms 5-7 weeks postinfusion were more likely to receive 5 mg/kg/6 weeks dosing (OR: 3.4, 95% CI: 1.4-8.8, P < 0.01). Early response to dose-intensification occurred in 69% of patients in the 6-week group and 67% in the double-dose group (P = N.S.). Regained response was maintained for 12 months in 40% compared with 29% of the patients respectively (P = N.S.).
CONCLUSION: In CD patients who lost response to standard infliximab dose, especially when symptoms re-emerge 5-7 weeks postinfusion, shortening the dosing interval to 6 weeks appears to be at least as effective as doubling the dose to 10 mg/kg or halving the infusion intervals to once in 4 weeks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 33(2011), 3 vom: 15. Feb., Seite 349-57 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kopylov, U [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 03.06.2011 Date Revised 10.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/j.1365-2036.2010.04523.x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM203984307 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM203984307 | ||
| 003 | DE-627 | ||
| 005 | 20231223231153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1365-2036.2010.04523.x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0680.xml |
| 035 | |a (DE-627)NLM203984307 | ||
| 035 | |a (NLM)21118397 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kopylov, U |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.06.2011 | ||
| 500 | |a Date Revised 10.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2010 Blackwell Publishing Ltd. | ||
| 520 | |a BACKGROUND: Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks | ||
| 520 | |a AIM: We sought to investigate the efficacy of a once every 6 weeks' strategy compared with dose-doubling | ||
| 520 | |a METHODS: This work was a multicentre retrospective study of infliximab-treated CD patients who required dose escalation. The clinical outcome of patients treated by intensification to 5 mg/kg/6 weeks (6-week group) was compared with the outcome of patients whose infliximab was double-dosed (10 mg/kg/8 weeks or 5 mg/kg/4 weeks) | ||
| 520 | |a RESULTS: Ninety-four patients (mean age: 29.8 years) were included in the study, 55 (59%) in the 6-week group and 39 (41%) in the double-dose group. Demographics and disease characteristics were similar between the two groups, although patients with re-emerging symptoms 5-7 weeks postinfusion were more likely to receive 5 mg/kg/6 weeks dosing (OR: 3.4, 95% CI: 1.4-8.8, P < 0.01). Early response to dose-intensification occurred in 69% of patients in the 6-week group and 67% in the double-dose group (P = N.S.). Regained response was maintained for 12 months in 40% compared with 29% of the patients respectively (P = N.S.) | ||
| 520 | |a CONCLUSION: In CD patients who lost response to standard infliximab dose, especially when symptoms re-emerge 5-7 weeks postinfusion, shortening the dosing interval to 6 weeks appears to be at least as effective as doubling the dose to 10 mg/kg or halving the infusion intervals to once in 4 weeks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 700 | 1 | |a Mantzaris, G J |e verfasserin |4 aut | |
| 700 | 1 | |a Katsanos, K H |e verfasserin |4 aut | |
| 700 | 1 | |a Reenaers, C |e verfasserin |4 aut | |
| 700 | 1 | |a Ellul, P |e verfasserin |4 aut | |
| 700 | 1 | |a Rahier, J F |e verfasserin |4 aut | |
| 700 | 1 | |a Israeli, E |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, P L |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorino, G |e verfasserin |4 aut | |
| 700 | 1 | |a Cesarini, M |e verfasserin |4 aut | |
| 700 | 1 | |a Tsianos, E V |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, E |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Horin, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 33(2011), 3 vom: 15. Feb., Seite 349-57 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2011 |g number:3 |g day:15 |g month:02 |g pages:349-57 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-2036.2010.04523.x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2011 |e 3 |b 15 |c 02 |h 349-57 | ||